Puma Biotechnology Inc (PBYI)
4.095
-0.32
(-7.14%)
USD |
NASDAQ |
May 17, 16:00
4.20
+0.10
(+2.56%)
After-Hours: 20:00
Puma Biotechnology Research and Development Expense (Annual): 50.38M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 50.38M |
| December 31, 2022 | 52.24M |
| December 31, 2021 | 71.87M |
| December 31, 2020 | 97.65M |
| December 31, 2019 | 132.85M |
| December 31, 2018 | 164.85M |
| December 31, 2017 | 207.81M |
| Date | Value |
|---|---|
| December 31, 2016 | 222.80M |
| December 31, 2015 | 208.47M |
| December 31, 2014 | 122.92M |
| December 31, 2013 | 45.05M |
| December 31, 2012 | 49.64M |
| December 31, 2011 | 0.826M |
| December 31, 2010 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
50.38M
Minimum
2023
132.85M
Maximum
2019
81.00M
Average
71.87M
Median
2021
Research and Development Expense (Annual) Benchmarks
| ADMA Biologics Inc | 3.30M |
| Pfizer Inc | 10.68B |
| United Therapeutics Corp | 408.00M |
| Vanda Pharmaceuticals Inc | 76.82M |
| Sarepta Therapeutics Inc | 877.39M |